1 Tian R, Zhang D, Yao X, et al. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study[J]. Ann Rheum Dis, 2023, 82(3): 351-356. PMID: 36241363. PMCID: PMC9933169. DOI: 10.1136/ard-2022-223035.
2 Levinsky Y, Broide M, Kagan S, et al. Performance of 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in a paediatric population: a multicentre study[J]. Rheumatology (Oxford), 2021, 60(11): 5142-5148. PMID: 33560345. DOI: 10.1093/rheumatology/keab140.
3 Brown GJ, Ca?ete PF, Wang H, et al. TLR7 gain-of-function genetic variation causes human lupus[J]. Nature, 2022, 605(7909): 349-356. PMID: 35477763. PMCID: PMC9095492. DOI: 10.1038/s41586-022-04642-z.
4 Fillatreau S, Manfroi B, D?rner T. Toll-like receptor signalling in B cells during systemic lupus erythematosus[J]. Nat Rev Rheumatol, 2021, 17(2): 98-108. PMID: 33339987. PMCID: PMC7747191. DOI: 10.1038/s41584-020-00544-4.
5 Meng Y, Ma J, Yao C, et al. The NCF1 variant p.R90H aggravates autoimmunity by facilitating the activation of plasmacytoid dendritic cells[J]. J Clin Invest, 2022, 132(16): e153619. PMID: 35788118. PMCID: PMC9374378. DOI: 10.1172/JCI153619.
6 Peng J, Wang Y, Han X, et al. Clinical implications of a new DDX58 pathogenic variant that causes lupus nephritis due to RIG-I hyperactivation[J]. J Am Soc Nephrol, 2023, 34(2): 258-272. PMID: 36261300. DOI: 10.1681/ASN.2022040477.
7 Sandling JK, Pucholt P, Hultin Rosenberg L, et al. Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing[J]. Ann Rheum Dis, 2021, 80(1): 109-117. PMID: 33037003. PMCID: PMC7788061. DOI: 10.1136/annrheumdis-2020-218636.
8 Han X, Gu S, Hong SM, et al. Amelioration of autoimmunity in a lupus mouse model by modulation of T-bet-promoted energy metabolism in pathogenic age/autoimmune-associated B cells[J]. Arthritis Rheumatol, 2023, 75(7): 1203-1215. PMID: 36575806. DOI: 10.1002/art.42433.
9 Sosa-Hernández VA, Romero-Ramírez S, Cervantes-Díaz R, et al. CD11c+ T-bet+ CD21hi B cells are negatively associated with renal impairment in systemic lupus erythematosus and act as a marker for nephritis remission[J]. Front Immunol, 2022, 13: 892241. PMID: 35663936. PMCID: PMC9160198. DOI: 10.3389/fimmu.2022.892241.
10 Abraham R, Durkee MS, Ai J, et al. Specific in situ inflammatory states associate with progression to renal failure in lupus nephritis[J]. J Clin Invest, 2022, 132(13): e155350. PMID: 35608910. PMCID: PMC9246394. DOI: 10.1172/JCI155350.
11 Sasaki T, Bracero S, Keegan J, et al. Longitudinal immune cell profiling in patients with early systemic lupus erythematosus[J]. Arthritis Rheumatol, 2022, 74(11): 1808-1821. PMID: 35644031. DOI: 10.1002/art.42248.
12 Zhang M, Johnson-Stephenson TK, Wang W, et al. Mesenchymal stem cell-derived exosome-educated macrophages alleviate systemic lupus erythematosus by promoting efferocytosis and recruitment of IL-17+ regulatory T cell[J]. Stem Cell Res Ther, 2022, 13(1): 484. PMID: 36153633. PMCID: PMC9509559. DOI: 10.1186/s13287-022-03174-7.
13 Bashant KR, Aponte AM, Randazzo D, et al. Proteomic, biomechanical and functional analyses define neutrophil heterogeneity in systemic lupus erythematosus[J]. Ann Rheum Dis, 2021, 80(2): 209-218. PMID: 32988843. PMCID: PMC7855438. DOI: 10.1136/annrheumdis-2020-218338.
14 Furie RA, van Vollenhoven RF, Kalunian K, et al. Trial of anti-BDCA2 antibody litifilimab for systemic lupus erythematosus[J]. N Engl J Med, 2022, 387(10): 894-904. PMID: 36069871. DOI: 10.1056/NEJMoa2118025.
15 Caielli S, Cardenas J, de Jesus AA, et al. Erythroid mitochondrial retention triggers myeloid-dependent type I interferon in human SLE[J]. Cell, 2021, 184(17): 4464-4479.e19. PMID: 34384544. PMCID: PMC8380737. DOI: 10.1016/j.cell.2021.07.021.
16 Fillatreau S. Antibodies against type I IFN: the bad guys self-restrain in systemic lupus erythematosus[J]. Cell Rep Med, 2023, 4(1): 100903. PMID: 36652912. PMCID: PMC9873922. DOI: 10.1016/j.xcrm.2022.100903.
17 Psarras A, Wittmann M, Vital EM. Emerging concepts of type I interferons in SLE pathogenesis and therapy[J]. Nat Rev Rheumatol, 2022, 18(10): 575-590. PMID: 36097207. DOI: 10.1038/s41584-022-00826-z.
18 宋红梅. 儿童风湿病国际相关诊治指南系列解读之一: EULAR-ACR系统性红斑狼疮分类标准解读[J]. 中国实用儿科杂志, 2020, 35(4): 249-252. DOI:10.19538/j.ek2020040601.
19 Rodrigues Fonseca A, Felix Rodrigues MC, Sztajnbok FR, et al. Comparison among ACR1997, SLICC and the new EULAR/ACR classification criteria in childhood-onset systemic lupus erythematosus[J]. Adv Rheumatol, 2019, 59(1): 20. PMID: 31092290. DOI: 10.1186/s42358-019-0062-z.
20 中华医学会儿科学分会肾脏学组. 狼疮性肾炎诊治循证指南（2016）[J]. 中华儿科杂志, 2018, 56(2): 88-94. DOI: 10.3760/cma.j.issn.0578-1310.2018.02.003.
21 张辉, 杨念生, 鲁静, 等. 狼疮肾炎诊疗规范[J]. 中华内科杂志, 2021, 60(9): 784-790. DOI:10.3760/cma.j.cn112138-20210609-00410.
22 Davidson A. Renal mononuclear phagocytes in lupus nephritis[J]. ACR Open Rheumatol, 2021, 3(7): 442-450. PMID: 34060247. PMCID: PMC8280821. DOI: 10.1002/acr2.11269.
23 Jesus D, Larosa M, Henriques C, et al. Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity[J]. Ann Rheum Dis, 2021, 80(12): 1568-1574. PMID: 34407927. DOI: 10.1136/annrheumdis-2021-220363.
24 Parra Sánchez AR, Voskuyl AE, van Vollenhoven RF. Treat-to-target in systemic lupus erythematosus: advancing towards its implementation[J]. Nat Rev Rheumatol, 2022, 18(3): 146-157. PMID: 35039665. DOI: 10.1038/s41584-021-00739-3.
25 Arnold J, Dass S, Twigg S, et al. Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab[J]. Rheumatology (Oxford), 2022, 61(12): 4905-4909. PMID: 35266512. DOI: 10.1093/rheumatology/keac150.
26 Urowitz MB, Aranow C, Asukai Y, et al. Impact of belimumab on organ damage in systemic lupus erythematosus[J]. Arthritis Care Res (Hoboken), 2022, 74(11): 1822-1828. PMID: 35439360. PMCID: PMC9805003. DOI: 10.1002/acr.24901.
27 Yao X, Ren Y, Zhao Q, et al. Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS/April fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis[J]. Eur J Pharm Sci, 2021, 159: 105704. PMID: 33440243. DOI: 10.1016/j.ejps.2021.105704.
28 Morand E, Pike M, Merrill JT, et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial[J]. Arthritis Rheumatol, 2023, 75(2): 242-252. PMID: 36369798. PMCID: PMC10100399. DOI: 10.1002/art.42391.
29 Merrill JT, Werth VP, Furie R, et al. Phase 2 trial of iberdomide in systemic lupus erythematosus[J]. N Engl J Med, 2022, 386(11): 1034-1045. PMID: 35294813. DOI: 10.1056/NEJMoa2106535.
30 Humrich JY, Cacoub P, Rosenzwajg M, et al. Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial[J]. Ann Rheum Dis, 2022, 81(12): 1685-1694. PMID: 35973803. DOI: 10.1136/ard-2022-222501.
31 Li Y, Tang D, Yin L, et al. New insights for regulatory T cell in lupus nephritis[J]. Autoimmun Rev, 2022, 21(8): 103134. PMID: 35690245. DOI: 10.1016/j.autrev.2022.103134.
32 Li Y, Liu H, Yan H, et al. Research advances on targeted-Treg therapies on immune-mediated kidney diseases[J].Autoimmun Rev, 2023, 22(2): 103257. PMID: 36563769. DOI: 10.1016/j.autrev.2022.103257.
33 Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial[J]. Lancet Rheumatol, 2019, 1(4): e208-e219.
34 Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus[J]. N Engl J Med, 2020, 382(3): 211-221. PMID: 31851795. DOI: 10.1056/NEJMoa1912196.
35 Chatham WW, Furie R, Saxena A, et al. Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: results of a phase II open-label extension study[J]. Arthritis Rheumatol, 2021, 73(5): 816-825. PMID: 33225631. PMCID: PMC8252065. DOI: 10.1002/art.41598.
36 Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial[J]. Lancet, 2021, 397(10289): 2070-2080. PMID: 33971155. DOI: 10.1016/S0140-6736(21)00578-X.
37 Hasni SA, Gupta S, Davis M, et al. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus[J]. Nat Commun, 2021, 12(1): 3391. PMID: 34099646. PMCID: PMC8185103. DOI: 10.1038/s41467-021-23361-z.
38 You H, Zhang G, Wang Q, et al. Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre[J]. Ann Rheum Dis, 2019, 78(10): 1441-1443. PMID: 31005902. DOI: 10.1136/annrheumdis-2019-215455.
39 K?nig N, Fiehn C, Wolf C, et al. Familial chilblain lupus due to a gain-of-function mutation in STING[J]. Ann Rheum Dis, 2017, 76(2): 468-472. PMID: 27566796. DOI: 10.1136/annrheumdis-2016-209841.
40 Lee J, Park Y, Jang SG, et al. Baricitinib attenuates autoimmune phenotype and podocyte injury in a murine model of systemic lupus erythematosus[J]. Front Immunol, 2021, 12: 704526. PMID: 34497607. PMCID: PMC8419414. DOI: 10.3389/fimmu.2021.704526.
41 Nakayamada S, Tanaka Y. Pathological relevance and treatment perspective of JAK targeting in systemic lupus erythematosus[J]. Expert Rev Clin Immunol, 2022, 18(3): 245-252. PMID: 35138987. DOI: 10.1080/1744666X.2022.2040988.
42 Fang T, Li B, Li M, et al. Engineered cell membrane vesicles expressing CD40 alleviate system lupus nephritis by intervening B cell activation[J]. Small Methods, 2023, 7(3): e2200925. PMID: 36605001. DOI: 10.1002/smtd.202200925.
43 Zhao Z, Jiang H, Xu X, et al. Polymeric dexamethasone prodrugs attenuate lupus nephritis in MRL/lpr mice with reduced glucocorticoid toxicity[J]. Nanomedicine, 2022, 44: 102579. PMID: 35768036. PMCID: PMC9427713. DOI: 10.1016/j.nano.2022.102579.
44 Zhang B, Sun J, Yuan Y, et al. Proximity-enabled covalent binding of IL-2 to IL-2Rα selectively activates regulatory T cells and suppresses autoimmunity[J]. Signal Transduct Target Ther, 2023, 8(1): 28. PMID: 36690610. PMCID: PMC9871032. DOI: 10.1038/s41392-022-01208-3.
45 Mougiakakos D, Kr?nke G, V?lkl S, et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus[J]. N Engl J Med, 2021, 385(6): 567-569. PMID: 34347960. DOI: 10.1056/NEJMc2107725.
46 Mackensen A, Müller F, Mougiakakos D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus[J]. Nat Med, 2022, 28(10): 2124-2132. PMID: 36109639. DOI: 10.1038/s41591-022-02017-5.